What is NovoCure's cash & equivalents?

NovoCure (NVCR) reported cash & equivalents of $87.53M in Q1 2026.

How has NovoCure's cash & equivalents changed year-over-year?

NovoCure's cash & equivalents decreased by 31.2% year-over-year, from $127.28M to $87.53M.

What is the long-term trend for NovoCure's cash & equivalents?

Over 5 years (2020 to 2025), NovoCure's cash & equivalents has grown at a -16.8% compound annual growth rate (CAGR), from $234.67M to $93.55M.

What does cash & equivalents mean?

Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

NovoCure NVCR Cash & Equivalents

Cash & Equivalents at other companies

Boston ScientificBSX

$850M+146%

MedtronicMDT

$1.95B-12.1%

Iovance Biotherapeutics, Inc.IOVA

$196.51M+14.5%

Nuvation BioNUVB

$125.39M+161%

Vir Biotechnology, Inc.VIR

$283.04M-23.1%

ArriVent BioPharma, Inc.AVBP

$62.1M+24.5%

Other financials

Income statement

See full

Revenue$174.1M+12.3%

Gross profit$135.1M+16.0%

Operating income-$67.4M-78.1%

Net income-$71.1M-107%

EPS (diluted)-$0.62-100%

Balance sheet

See full

Total debt$39.5M-2.1%

Total equity$330.7M-8.6%

Total assets$787.9M-36.9%

Cash flow

See full

Operating cash flow-$13.5M+62.1%

CapEx$5.2M-51.4%

Free cash flow-$18.7M+59.7%

Valuation

See full

Market cap$1.64B-36.7%

Enterprise value$1.59B-36.3%

P/S2.4×-1.7×

Profitability

See full

Gross margin75.2%-2.0pp

Operating margin-27.2%+0.4pp

Net margin-25.7%-0.7pp

FCF margin-7.1%-2.0pp

Returns & leverage

See full

Return on equity-50%+5.4pp

Debt / equity0.1×0.0×

Current ratio2.9×+1.4×

Where this comes from

Reported directly by NovoCure in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: NovoCure’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about NovoCure's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is NovoCure's cash & equivalents?: NovoCure (NVCR) reported cash & equivalents of $87.53M in Q1 2026.
How has NovoCure's cash & equivalents changed year-over-year?: NovoCure's cash & equivalents decreased by 31.2% year-over-year, from $127.28M to $87.53M.
What is the long-term trend for NovoCure's cash & equivalents?: Over 5 years (2020 to 2025), NovoCure's cash & equivalents has grown at a -16.8% compound annual growth rate (CAGR), from $234.67M to $93.55M.
What does cash & equivalents mean?: Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.